Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)

NCT02588859 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02588859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02588859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
October 30, 2015
Completion date
December 26, 2016
Enrollment
1,200 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes